BEKE vs REG

BEKE's deterministic health scores signal significant distress: the Piotroski F-Score of 3/9 indicates weak financial health, with deteriorating profitability and negative earnings growth. The absence of an Altman Z-Score raises red flags for potential bankruptcy risk, especially given the company's declining earnings and high payout ratio. While the Graham Number ($9.15) suggests undervaluation, the current price of $16.90 trades at a substantial premium, reflecting overoptimistic growth expectations. Analysts recommend 'buy' with a target of $20.68, but this is inconsistent with the company's weak fundamentals and negative earnings trajectory. The stock has underperformed over multiple time horizons, including a 5-year decline of 73.3%.

REG exhibits stable operational health with a Piotroski F-Score of 6/9 and strong credit ratings (A-/A3), but is currently facing valuation and sustainability headwinds. While the stock trades near its growth-based intrinsic value ($83.19), it is significantly above its defensive Graham Number ($48.21). The operational strength—evidenced by 96.1% occupancy and positive rent spreads—is offset by a concerning dividend payout ratio of 101.77% and aggressive insider selling across the C-suite. Consequently, the stock appears fully valued with limited immediate upside.